How to Detect the Early Cardiac Functional Change and Predict Heart Failure in Paroxysmal Atrial Fibrillation? A Prospective Cohort Study

Lei Cheng; Lilian Bao; Xinyu Zhuang; Fangying Yan; Xiufang Gao; Peng Zhou; Yikai Zhao; Ke Yang; Qi Zhang; Guoqian Huang; Liwen Bao

doi:10.1101/2024.06.26.24309561

Abstract

Backgrounds 20-30% atrial fibrillation (AF) may result in heart failure (HF). Noninvasive left ventricle myocardial work (LVMW) is a fairly new method for detecting LV function. We aimed to evaluate whether LVMW could detect the LV change function in paroxysmal atrial fibrillation (PAF) and predict HF incident.

Methods In this prospective cohort study, 146 PAF subjects and 63 non-PAF subjects matched by age and gender set as the controls were enrolled. Noninvasive LVMW parameters, including global work index, global constructive work, global wasted work (GWW) and global work efficiency (GWE) were obtained from LV pressure-strain loop by 2D speckle tracking imaging. LA volume index (LAVI) was measured by 3D echocardiography. AF burden (AFB) was evaluated by questionnaire. The primary outcome was the incident HF.AFB deterioration was evaluated at the end of follow up. Stata15.0 and R4.1 were used for data analysis and description.

Results The average age was 66.2±11.4 years and comprised 55% males in PAF. Compared with the controls, PAF had significantly elevated GWW (143.7±88.3mmHg% vs 115.5±59.6mmHg%, p<0.001) and impaired GWE (92.3±7.5% vs 93.8±2.8%, p=0.035) and they were correlated with increased LAVImax and LAVImin. Those with higher AFB showed significantly decreased LAEF and increased LAVImin. During the average 40.5 months follow-up, 9.9% PAF developed HF and ablation reduced the HF occurrence. In the non-ablation subgroup, baseline decreased LAEF rather than LVMW was a strong predictor for HF. As expected, AFB deterioration was strongly associated with HF incident.

Conclusions Elevated GWW was detected by LVMW and it was strongly correlated with LA dilation in PAF. Higher AFB had adverse effect on LAVImin. Restoring sinus rhythm was significant for HF prevention, especially for PAF with lower LAEF.

What is new?

Although GLS and LVEF remained normal, subtle LV dysfunction of elevated GWW and impaired GWE could be detected by LVMW in the early stage of PAF.
Increased LAVImin, rather than LAEF, was strongly associated with elevated GWW and higher AF burden in PAF.
Restoring sinus rhythm was important to early stage of PAF for HF prevention, especially in PAF with lower LAEF.

What are the clinical implications?

It is significant for PAF to protect LV function by maintaining sinus rhythm or keeping AFB at minimal-mild stage, even from the very early stage.
Increased LAVImin is an important indicator for detecting LV dysfunction in PAF and the underlying mechanism needs to be discovered.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

The study protocol had been approved by the institute's committee on human research from Huashan Hospital, Fudan University (2020-788). However, this was a first single-centre prospective study with small sample size for us, so we did not register it on ClinicalTrials.gov et al.

Funding Statement

This work was supported by the grant from Science and Technology Commission of Shanghai Municipality.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol had been approved by the institute's committee on human research from Huashan Hospital, Fudan University (2020-788).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes